TransCode Therapeutics ( (RNAZ)) just unveiled an announcement. On December 19, 2025, TransCode Therapeutics appointed veteran life sciences executive Jack E. Stover to its board of directors, ...

BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, ...

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company’s lead therapeutic candidate ...

Carley Millhone is a writer and editor based in the Midwest who covers health, women's wellness, and travel. Her work has appeared in publications like SELF, Greatist, and PureWow. Jay N. Yepuri, MD, ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...

Kourtnee covers TV streaming services and home entertainment. She previously worked as an entertainment reporter at Showbiz Cheat Sheet, where she wrote about film, television, music, celebrities and ...

Julia is the associate news editor for Health, where she edits and publishes news articles on trending health and wellness topics. Her work has been featured in The Heights, an independent student ...

TransCode Therapeutics has developed an iron oxide nanoparticle–based therapeutic RNA delivery system that maximizes targeted tumor uptake while minimizing clearance. With a lead candidate in ...

Entering text into the input field will update the search result below Entering text into the input field will update the search result below ...